Sirker A, et al. - Researchers assessed outcomes related to different P2Y12 agents in saphenous vein graft (SVG) percutaneous coronary intervention (PCI) in a real world national study. Adjustment for baseline imbalances was carried out using multiple logistic regression and (separately) propensity score matching. Clopidogrel was used to treat most cases, followed by Ticagrelor and Prasugrel. No clear evidence was found to demonstrate that potent P2Y12 blockers, when used to treat SVG PCI, resulted in improved clinical outcomes.